Acute-phase ITIH4 levels distinguish multi-system from single-system Langerhans cell histiocytosis via plasma peptidomics

Table 2 Clinical characteristics of patients with LCH-RO (−) or non-LCH

Patients	Age	Sex	Diagnosis (subtype)	Distribution of LCH lesions
L1	3 years 0 month	M	MS-LCH	Parietal bone, Ear canal, Lung
L2	7 years 0 month	F	MS-LCH	Bone, Skin, Pituitary gland
L3	4 years 10 months	M	MS-LCH	Skin, Bone, Pituitary gland, CNS
L4	1 year 0 month	M	MS-LCH	Bone, Orbit
L5	11 years 4 months	F	MS-LCH	Bone, Pituitary gland
L6	11 years 11 months	M	SS-LCH	Bone
L7	4 years 11 months	F	SS-LCH	Bone
L8	9 years 0 month	M	SS-LCH	Bone
L9	6 years 0 month	M	SS-LCH	Bone
L10	1 years 0 month	F	SS-LCH	Skin
L11	4 years 4 months	F	SS-LCH	Bone
L12	1 years 3 months	M	SS-LCH	Bone
C1	2 years 4 months	F	Toxicoderma	−
C2	2 years 3 months	M	Kawasaki disease	−
C3	10 years 0 month	F	SLE	−
C4	2 years 3 months	M	ITP	−
C5	1 year 11 months	M	Kawasaki disease	−

The median age of the MS-LCH patients (n = 5) was 4 years, 10 months (range: 1 year, 0 months–11 years, 4 months). The median age of the SS-LCH patients (n = 7) was 4 years, 11 months (range: 1 year, 0 months–11 years, 11 months). The median age of non-LCH patients (n = 5) was 2 years, 3 months (range: 1 year, 3 months–10 years, 0 months). Abbreviations: CNS central nervous system, ITP idiopathic thrombocytopenic purpura, LCH Langerhans cell histiocytosis, LCH-RO (−) LCH with no involvement of high-risk organ (spleen, liver, and bone marrow), MS-LCH multisystem LCH, SLE systemic lupus erythematosus, SS-LCH single-system LCH

ISSN: 1559-0275